Newborn SCID screening study aims to unlock secrets of immune disorders
NCT ID NCT07704281
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This study follows infants who had a positive newborn screening test for severe combined immunodeficiency (SCID), a group of genetic disorders that leave babies vulnerable to life-threatening infections. Researchers will track these children to identify the underlying causes of their low T-cell counts and describe how they are managed in clinical care. The goal is to better understand SCID and related conditions, improving early diagnosis and treatment strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could improve early detection and treatment of severe immune disorders in newborns, potentially saving lives.
- What could go wrong
- This is an observational follow-up study, not a treatment trial. It may not directly lead to new therapies, and results depend on data completeness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE COMBINED IMMUNODEFICIENCIES (SCID) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Nantes university hospital
Nantes, 44093, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••